Neuromodulation is the physiological process by which a given neuron uses one or more chemicals to regulate diverse populations of neurons. A neuromodulator can be conceptualized as a neurotransmitter that is not reabsorbed by the pre-synaptic neuron or broken down into a metabolite. Neuromodulators typically bind to metabotropic, G-protein coupled receptors (GPCRs) to initiate a second messenger signaling cascade that induces a broad, long-lasting signal. This modulation can last for hundreds of milliseconds to several minutes. Some of the effects of neuromodulators include: alter intrinsic firing activity, increase or decrease voltage-dependent currents, alter synaptic efficacy, increase bursting activity and reconfiguration of synaptic connectivity.

Major neuromodulators in the central nervous system include: dopamine, serotonin, acetylcholine, histamine, norepinephrine, nitric oxide, and several neuropeptides. Cannabinoids can also be powerful CNS neuromodulators.

Acetylcholine

Acetylcholinesterase (EC 3.1.1.7, e.g. from Torpedo californica, TcAChE) hydrolysizes the neurotransmitter acetylcholine , producing group. ACh directly binds (via its nucleophilic Oγ atom) within the catalytic triad of (ACh/TcAChE structure 2ace). The residues are also important in the ligand recognition. After this binding acetylcholinesterase ACh.

Acetylcholine Receptors

Nicotinic acetylcholine receptors

• Nicotinic Acetylcholine Receptors in general

The receptor is a transmembrane pentameric glycoprotein. It cylindrical in appearance by electron microscopy approximately 16nm in length and 8nm in diameter. The main ion channel is composed of a water pore that runs through the entire length of the protein. If viewed from the synaptic cleft, the protein will look like a pseudo-symmetrical rosette shown in the picture below composed of 10 different alpha and 4 different beta subunits.

• .
• .
• .

• Alpha-bungarotoxin is a nicotinic cholinergic antagonist that is found within the venom of Bungarus multicinctus, a South-asian snake.
• Binding site of AChR
• Acetylcholine Receptor and its Reaction to Cobra Venom

When cobra venom is introduced into the body is moves along the bloodstream to a diaphragm muscle. It works as a postsynaptic neurotoxin binding to the receptor as an extracellular ligand by interacting with OH group leaving the acetylcholine channel open which releases ions used in creating an action potential. There must be 5 molecules of cobra toxin (red) to block the receptor (blue) as each molecule binds with an individual alpha chain on the acetylcholine receptor. The 2nd image depicts an individual toxin binding with one chain on the receptor, both in the same color. . This representation shows each molecule of the .

Muscarinic acetylcholine receptors

M1, M3, M5 receptors are coupled with G_q proteins, while M2 and M4 receptors are coupled with G_i/o proteins. They belong to GPCRs Subfamily A18.

• Muscarinic acetylcholine receptor

Acetylcholinesterase

• Acetylcholinesterase: Treatment of Alzheimer's disease
  
• Torpedo californica acetylcholinesterase with bifunctional inhibitor
  
• Acetylcholinesterase: Substrate Traffic and Inhibition
  
• Acetylcholinesterase Inhibitor Pharmacokinetics
  
• Acetylcholinesterase inhibitors
  
• AChE inhibitors and substrates
  
• Human Acetylcholinesterase
  
• African Malaria Mosquito Acetylcholinesterase
  
• Acetylcholinesterase inhibited by nerve agent soman
  
• Acetylcholinesterase with DFP
  
• Acetylcholinesterase with OTMA
  
• Acetylcholinesterase with acetylcholine
  
• Acetylcholinesterase complexed with N-9-(1',2',3',4'-tetrahydroacridinyl)-1,8-diaminooctane
  
• Complex of TcAChE with an iminium galanthamine derivative
  
• Complex of TcAChE with bis-acting galanthamine derivative
  
• Cholinesterase
  
• Flexibility of aromatic residues in acetylcholinesterase
  
• Huperzine A Complexed with Acetylcholinesterase & Huperzine A Complexed with Acetylcholinesterase (Chinese)
  
• Acetylcholinesterase complexed with Tacrine, the 1st anti Alzheimer's drug
  
• UMass Chem 423 Student Projects 2011-1: Acetylcholinesterase bound by Tacrine
• Torpedo Californica Acetylcholinesterase in complex with an (R)-Tacrine-(10)-Hupyridone inhibitor
  
• Torpedo Californica Acetylcholinesterase in complex with an (S)-Tacrine-(10)-Hupyridone inhibitor
  
• Torpedo californica acetylcholinesterase with alkylene-linked tacrine dimer (5 carbon linker)
  
• Torpedo californica acetylcholinesterase with alkylene-linked tacrine dimer (7 carbon linker)
  
• Torpedo californica acetylcholinesterase with bifunctional inhibitor
  
• Tetramerization domain of acetylcholinesterase
  
• African Malaria Mosquito Acetylcholinesterase
• Group:SMART:Acetylcholinesterase:A Story of Substrate Traffic and Inhibition by Green Mamba Snake Toxin
  
• Treatments:AChE Inhibitor References
  

Adrenaline (Epinephrine)/Noradrenaline (Norepinephrine)

• .
• .
• Phenylethanolamine N-methyltransferase (Noradrenaline N-Methyltransferase) catalyzes the conversion of norepinephrine (noradrenaline) to epinephrine (adrenaline). This is the last step in the conversion of tyrosine to adrenaline^[1].

Adrenergic receptors in general

The adrenergic receptors are metabolic G protein-coupled receptors. They are the targets of catecholamines. The binding of an agonist to them causes a sympathetic response.

• The α-2 adrenergic receptor (A2AR) inhibits insulin or glucagons release.
  
• The β-1 adrenergic receptor (B1AR) increases cardiac output and secretion of rennin and ghrelin.^[2]
  
• The β-2 adrenergic receptor (B2AR) triggers many relaxation reactions.

β1 adrenergic receptor

• 3D structures in Adrenergic receptor.
• Beta-1 Adrenergic receptor
• G_s: adenylate cyclase activated, cAMP up.

• β1-adrenergic agonists:
  • Dobutamine, see Beta-1 Adrenergic receptor, 2y00, 2y01, 6h7l.
  • Isoprenaline, see Beta-1 Adrenergic receptor, 2y03.
  • Noradrenaline
  • Carmoterol, see 2y02.
  • Salbutamol (Albuterol in USA), 2y04.
• Beta blockers:
  • Metoprolol
  • Atenolol
  • Bisoprolol
  • Propranolol
  • Timolol
  • Nebivolol
  • Vortioxetine

β2 adrenergic receptor

• The human β2 adrenergic receptor bound to a G-protein (3sn6) is featured in a scene above, and additional structures are on the Adrenergic receptor page.
• Article Beta-2 Adrenergic Receptor by Wayne Decatur, David Canner, Dotan Shaniv, Joel L. Sussman, Michal Harel
• Article Beta-2 adrenergic receptor by Joel L. Sussman, Tala Curry, Michal Harel, Jaime Prilusky
• Group:SMART:A Physical Model of the beta-Adrenergic Receptor
• G_s: adenylate cyclase activated, cAMP up. For G_s see Beta2 adrenergic receptor-Gs protein complex updated.

β2-adrenergic agonists:

• • Salbutamol (Albuterol in USA)
  • Bitolterol mesylate
  • Formoterol
  • Isoprenaline
  • Levalbuterol
  • Metaproterenol
  • Salmeterol
  • Terbutaline
  • Ritodrine
• Beta blockers:
  • Butoxamine
  • Timolol
  • Propranolol
  • ICI-118,551
  • Paroxetine

Beta-adrenergic receptor kinase

Monoamine oxidases (MAO)

Monoamine oxidases (MAO) (EC 1.4.3.4) are a family of enzymes that catalyze the oxidation of monoamines including adrenaline, noradrenaline, serotonin and dopamine.

Monoamine oxidase

Monoamine oxidase b

Dopamine

DOPA decarboxylase

Dopamine Receptors

Dopamine receptors are a class of metabotropic G protein-coupled receptors that are important in the central nervous system. Dopamine receptors are involved in many neurological processes that comprise motivation, pleasure, cognition, memory, learning, and fine motor skills. There are five subtype dopamine receptors, D1, D2, D3, D4, and D5. The D3 receptor is a part of the D2-like family.^[3]

• Dopamine receptors 1 page
• Dopamine receptors 2 page

Agonists

• Amphetamine^[4]
• Methamphetamine^[5]

Antagonists

• Clebopride^[6]
• Nafadotride^[7]
• Eticlopride.

(3pbl).

.

Parkinson's disease

DOPA decarboxylase is responsible for the synthesis of dopamine and serotonin from L-DOPA and L-5-hydroxytryptophan, respectively. It is highly stereospecific, yet relatively nonspecific in terms of substrate, making it a somewhat uninteresting enzyme to study. Although it is not typically a rate-determining step of dopamine synthesis, the decarboxylation of L-DOPA to dopamine by DDC is the controlling step for individuals with Parkinson's disease^[8], the second most common neurodegenerative disorder, occuring in 1% of the population over the age of 65. The loss of dopaminergic neurons is the main cause of cognitive impairment and tremors observed in patients with the disease. The hallmark of the disease is the formation of alpha-synuclein containing Lewy bodies.

Currently, treatment for the disease is aimed at DOPA decarboxylase inhibition. Since dopamine cannot cross the blood-brain barrier, it cannot be used to directly treat Parkinson's disease. Thus, exogenously administered L-DOPA is the primary treatment for patients suffering from this neurodegenerative disease. Unfortunately, DOPA decarboxylase rapidly converts L-DOPA to dopamine in the blood stream, with only a small percentage reaching the brain. By inhibiting the enzyme, greater amounts of exogenously administered L-DOPA can reach the brain, where it can then be converted to dopamine. ^[9]. Unfortunately, with continued L-Dopa treatment, up to 80% of patients experience 'wearing-off' symptoms, dyskinesias and other motor complications (referred to as the "on-off phenomenon". ^[10]. Clearly, a better understanding of the catalytic mechanism and enzymatic activity of DDC in both healthy and PD individuals is critical to drug design and treatment of the disease.

GABA

GABA receptors

GABA (i.e. gamma-aminobutyric acid) is the primary inhibitory neurotransmitter of the vertebrate central nervous system. GABA can bind one of two different receptor proteins, each using a discrete mechanism to elicit a cellular response. Upon binding with GABA, GABAB receptors (metabotropic) utilize a second messenger amplification pathway that ultimately results in an inhibitory signal for neuronal transmission. This pathway for signal transmission differs from GABAA receptors (ionotropic), which are considered ligand-gated ion channels as the binding of GABA results in the opening of ion channels leading to the inhibition of a neuronal signal. (PDB code 4ms3).

• GABA receptor
• User:Rana Saad/The human GABAb receptor
• GABAA receptor

GABA(A) receptor-associated protein